Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
- Luis M.A. Oliveira*
- , Thomas Gasser
- , Robert Edwards
- , Markus Zweckstetter
- , Ronald Melki
- , Leonidas Stefanis
- , Hilal A. Lashuel
- , David Sulzer
- , Kostas Vekrellis
- , Glenda M. Halliday
- , Julianna J. Tomlinson
- , Michael Schlossmacher
- , Poul Henning Jensen
- , Julia Schulze-Hentrich
- , Olaf Riess
- , Warren D. Hirst
- , Omar El-Agnaf
- , Brit Mollenhauer
- , Peter Lansbury
- , Tiago F. Outeiro*
*Corresponding author for this work
- Michael J. Fox Foundation for Parkinson's Research
- University of Tübingen
- German Center for Neurodegenerative Diseases
- University of California at San Francisco
- Max Planck Institute for Biophysical Chemistry (Karl Friedrich Bonhoeffer Institute)
- Commissariat à l’énergie atomique et aux énergies alternatives
- Academy of Athens
- National and Kapodistrian University of Athens
- Swiss Federal Institute of Technology Lausanne
- Columbia University
- University of Sydney
- University of Ottawa
- Aarhus University
- Biogen IDEC
- University of Göttingen
- Paracelsus-Elena-Klinik
- Lysosomal Therapeutics Inc.
- Max Planck Institute of Experimental Medicine
- Newcastle University
Research output: Contribution to journal › Review article › peer-review
119
Link opens in a new tab
Citations
(Scopus)